Is Amgen (AMGN) Expensive On Strong Q3 Results And Pipeline Progress?
Is Amgen (AMGN) Expensive On Strong Q3 Results And Pipeline Progress? Simply Wall St
Covered in this story
Analyst targets on Amgen
- Freedom Broker: at $460 · target $470 by Nov 2027 · Hold via Investing.com
- Oppenheimer: at $439 · target $480 by Oct 2027 · Outperform via Investing.com India
- Wells Fargo: at $432 · target $430 by Oct 2027 · equal weight via MarketBeat
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 30 Mar 2026.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.